SINOVAC COVID-19 Vaccine’s first real-world protection data released!
- Will CAR-NK Cancer Therapy Surpass High-Cost CAR-T Immunotherapy?
- What is the role of Platelet Dynamics in Cancer Progression?
- Biomarkers can detect rapid aging of organs and disease risks
- Avoiding “Off-Target” Effects: Researchers Enhance the Safety of Future mRNA Therapies
- Japan: Sales Halted for ‘Cannabis Gummies’ as Health Issues Mount
- Evaluation of the carcinogenicity of organic fluorine compounds raised by WHO subsidiary
SINOVAC COVID-19 Vaccine’s first real-world protection data released!
SINOVAC COVID-19 Vaccine’s first real-world protection data released! With the widespread vaccination of vaccines around the world, the questioning of SINOVAC (Kexing) vaccines has never stopped.
On July 7, 2021, the Chilean Ministry of Health reported in the New England Journal of Medicine (NEJM), the most well-known medical journal, the real-world protection results of SINOVAC (Kexing) inactivated virus vaccine in Chile.
This is also the first real-world protection data of Kexing vaccine, which immediately attracted a lot of attention.
This study of 10.2 million people pointed out that the full vaccination of Kexing vaccine is 65.9% for symptomatic COVID-19, 87.5% for preventing hospitalization, 90.3% for preventing income from ICU, and 90.3% for preventing COVID-19. 19 Death protection is 86.3%.
The study was conducted from February 2 to May 1, 2021, and included subjects over 16 years of age; the statistical analysis was adjusted for demographic and clinical characteristics.
The main observation indicators are shown in Table 2.
- As mentioned earlier, complete vaccination with Kexing vaccine has a 65.9% protection against symptomatic COVID-19;
- The protection against hospitalization is 87.5%;
- ICU protection for preventive income is 90.3%;
- The protection against death from COVID-19 is 86.3%.
However, only one dose of Kexing vaccine has very weak protection, followed by 15.5% for symptomatic COVID-19; 37.4% for prevention of hospitalization; 44.7% for prevention of income in ICU; and 44.7% for prevention of COVID-19 -19 Death protection is 45.7%.
The protection of people aged 60 and above is the key to vaccination.
The results are shown in Table 3.
- For the elderly, complete vaccination with Kexing vaccine has 66.6% protection against symptomatic COVID-19;
- The protection against hospitalization is 85.3%;
- ICU protection for preventive income is 89.2%;
- The protection against death from COVID-19 is 86.5%.
Summary:
Complete vaccination of Kexing vaccine is 65.9% for symptomatic COVID-19; 87.5% for prevention of hospitalization; 90.3% for prevention of income to ICU; and 86.3% for prevention of death from COVID-19.
However, only one dose of Kexing vaccine has very weak protection, followed by 15.5% for symptomatic COVID-19; 37.4% for prevention of hospitalization; 44.7% for prevention of income in ICU; and 44.7% for prevention of COVID-19 -19 Death protection is 45.7%.
The study did not distinguish the protection of Kexing vaccine against different virus strains.
Links to the full text of references: https://www.nejm.org/doi/full/10.1056/NEJMoa2107715
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
